Press Release - 17 April 2018

(只提供英文版本)Cordlife Earns Prestigious AABB Accreditation in Malaysia; Singapore and Hong Kong Facilities Re-accredited

SINGAPORE, 17 April 2018 – Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the "Group") announced today that majority-owned Stemlife Berhad, Malaysia’s pioneer and largest cord blood bank, received its first-ever world-class accreditation. Cordlife’s Singapore and Hong Kong facilities have also been re-accredited by blood banking authority AABB.

AABB is a global leader in developing standards for blood banking, transfusion medicine, blood management and cellular therapies. Cordlife Singapore was initially accredited by AABB in 2005, becoming the first private cord blood bank in Southeast Asia to receive such esteemed recognition, while Cordlife Hong Kong earned its first in 2011. With AABB qualification, transplant physicians can be assured that cord blood units managed and stored by the Group have been handled according to the highest standards to support successful transplants anywhere in the world. To date, the Group has released cord blood units for the treatment of leukaemia, thalassemia major, cerebral palsy and other disorders to hospitals from eight countries. The Group is also one of the first private cord blood banks in Asia to release cord blood units for transplants and cellular therapy.

"There is no room for error when it comes to collecting, processing and storing cord blood, cord lining and cord tissue," said Mr Michael Weiss, Group CEO and Executive Director of Cordlife. "Families who chose to store in unaccredited facilities should be made aware that standards could potentially fall short. Given lives could be at stake, we do not take standards lightly."

Besides AABB, Cordlife Singapore is also accredited by FACT (Foundation for the Accreditation of Cellular Therapy), another world-class international accreditation body for cord blood banks in the world. This makes Cordlife Singapore one of just six cord blood banks in the world to be accredited by both AABB and FACT. Within the Group, facilities across Asia are also accredited by other leading standards organisations, such as ISO and the College of American Pathologists.

The endorsement from AABB reaffirms the Group’s commitment to quality for safe patient and donor care; as well as to upholding the highest standards in the collection, testing, processing and storage of cord blood, cord lining and cord tissue.

"Accreditation in Malaysia and re-accreditation in Singapore and Hong Kong yet again demonstrate our medical, technical and administrative competence, and make testament to the world-class service quality and reliability that our clients have come to expect," Mr Weiss remarked.


 

您可能也會對以下文章感興趣...


臍帶血及臍帶治療案例

最新治療及臨床研究資訊

為了能夠令各位父母對臍帶血及臍帶資訊有更深厚的認識,生寶會定期更新世界各地的最新移植案例…

生寶里程碑

生寶里程碑

香港生寶成立於 2006 年,致力為各位父母提供最優質的臍帶及臍帶血儲存服務。多年來生寶考獲多項國際專業認證…

產前講座及活動

產前講座及活動

生寶每月均會舉辦免費產前講座,分享臍帶血及臍帶幹細胞的醫療應用、保存技術及成功移植案例等資訊,出席孕婦可獲贈精美禮品乙份…

生寶實驗室之旅

生寶實驗室之旅

由人工智能 Lisi 帶領各位準父母參觀生寶實驗室,安坐家中亦可以了解到生寶的高端設備如何守護寶寶珍貴的幹細胞資源。

安康檢™

初生嬰兒代謝病篩查

安康檢™由日本研發,專門為初生嬰兒而設的代謝病篩查服務,可檢測超過 100 種代謝病。及早發現代謝病可防止長遠影響寶寶的健康及發展。